Date published: 2026-5-17

1-800-457-3801

SCBT Portrait Logo
Seach Input

PLP-L Activators

The chemical class described as PLP-L Activators encompasses a range of compounds known for their ability to modulate signaling pathways which, in turn, can influence the activity of the protein PLP-L. These activators interact with a variety of cellular mechanisms. For instance, some activators in this class are inhibitors of specific kinases associated with the JAK-STAT signaling pathway. By inhibiting these kinases, the activators can alter the phosphorylation states of proteins within the pathway, leading to changes in gene expression that can affect PLP-L activity. Other activators within this class target the MAPK/ERK and PI3K/Akt pathways, which are crucial for regulating cell growth, differentiation, and survival. The inhibition or alteration of these pathways by the activators can result in a cascade of cellular responses, influencing the expression and function of PLP-L.

Moreover, the PLP-L Activators include compounds that can affect gene expression by modifying chromatin structure, thereby influencing the transcriptional landscape of cells, which includes the genes related to PLP-L. Some activators work by increasing cellular levels of secondary messengers, such as cAMP, which play a pivotal role in cellular signaling processes and can modulate a variety of pathways that affect PLP-L activity. By engaging with these intricate cellular processes, the PLP-L Activators can lead to adjustments in the activity levels of PLP-L, despite the absence of direct interaction with the protein itself. The actions of these activators are based on the interplay with and modulation of the endogenous signaling networks within which PLP-L operates.

SEE ALSO...

Items 1 to 10 of 11 total

Display:

Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

Tyrphostin B42

133550-30-8sc-3556
5 mg
$26.00
4
(1)

A tyrosine kinase inhibitor that primarily targets JAK2; by inhibiting JAK2, it could possibly activate Prl5a1 by affecting the JAK-STAT pathway.

Stat3 Inhibitor III, WP1066

857064-38-1sc-203282
10 mg
$132.00
72
(1)

An inhibitor of JAK2 and STAT3, potentially altering STAT3 phosphorylation and could possibly activate Prl5a1 through the JAK-STAT signaling pathway.

LY 294002

154447-36-6sc-201426
sc-201426A
5 mg
25 mg
$123.00
$400.00
148
(1)

A potent inhibitor of PI3K, which could possibly activate Prl5a1 by increasing compensatory signaling through the JAK-STAT pathway.

Wortmannin

19545-26-7sc-3505
sc-3505A
sc-3505B
1 mg
5 mg
20 mg
$67.00
$223.00
$425.00
97
(3)

Another PI3K inhibitor that could possibly activate Prl5a1 by altering downstream signaling in the PI3K/Akt pathway.

PD 98059

167869-21-8sc-3532
sc-3532A
1 mg
5 mg
$40.00
$92.00
212
(2)

A MEK inhibitor that could possibly activate Prl5a1 by influencing the MAPK/ERK pathway, possibly resulting in altered signaling.

U-0126

109511-58-2sc-222395
sc-222395A
1 mg
5 mg
$64.00
$246.00
136
(2)

A selective inhibitor of MEK1/2, which could possibly activate Prl5a1 by disrupting the MAPK/ERK signaling pathway.

Rapamycin

53123-88-9sc-3504
sc-3504A
sc-3504B
1 mg
5 mg
25 mg
$63.00
$158.00
$326.00
233
(4)

An mTOR inhibitor that could possibly activate Prl5a1 by disrupting PI3K/Akt/mTOR signaling and possibly influencing downstream effects.

SB 203580

152121-47-6sc-3533
sc-3533A
1 mg
5 mg
$90.00
$349.00
284
(5)

A specific inhibitor of p38 MAPK that could possibly activate Prl5a1 by affecting the MAPK pathway.

SP600125

129-56-6sc-200635
sc-200635A
10 mg
50 mg
$40.00
$150.00
257
(3)

An inhibitor of JNK, part of the MAPK signaling pathways, which could possibly activate Prl5a1 by affecting overall pathway activity.

Trichostatin A

58880-19-6sc-3511
sc-3511A
sc-3511B
sc-3511C
sc-3511D
1 mg
5 mg
10 mg
25 mg
50 mg
$152.00
$479.00
$632.00
$1223.00
$2132.00
33
(3)

A histone deacetylase inhibitor that could possibly activate Prl5a1 by affecting chromatin structure and gene expression.